Radx independent test assessment program for mpox lesion panel - commercialization center
Ended Awarded Last action
- Contract number
- 75N92023F00003
- Awardee
-
National Collegiate Inventors & Innovators Alliance, Inc. UEI D5S9JZ1KDP49
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,409,740
Award facts
- Contract value 100% obligated
- $1,409,739.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541618 Other Management Consulting Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Hadley, MA 01035, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $749,977 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $659,763 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1.41M firm fixed-price delivery order to National Collegiate Inventors & Innovators Alliance, Inc. (doing business as Venturewell) on September 27, 2023, for the RADx Independent Test Assessment Program for Mpox Lesion Panel—Commercialization Center. The contract, which has no small business set-aside designation, is scheduled for completion by June 30, 2026, and will be performed at Venturewell's headquarters in Hadley, Massachusetts. This delivery order supports the Rapid Acceleration of Diagnostics (RADx) initiative, a federal program focused on accelerating the development and commercialization of diagnostic technologies to address public health priorities.
Venturewell is a non-profit organization with extensive experience managing innovation and commercialization programs for federal agencies, particularly the National Institutes of Health. Under this contract, the organization will provide clinical evaluation services and commercialization support for monkeypox diagnostic technologies, building on its established track record of supporting RADx efforts across multiple disease areas including COVID-19 and HIV. The award is issued under Venturewell's existing indefinite delivery contract with NIAID for RADx clinical evaluation services, which carries a $58M ceiling value and allows the organization to establish and operate specialized commercialization centers for diagnostic technologies.
Quick answers
Who was awarded contract 75N92023F00003?
75N92023F00003 was awarded to National Collegiate Inventors & Innovators Alliance, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 27, 2023.
How much is contract 75N92023F00003 worth?
The government has obligated $1,409,740 on 75N92023F00003.
Which agency awarded contract 75N92023F00003?
National Heart Lung and Blood Institute (National Institutes of Health) awarded 75N92023F00003, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N92023F00003 an order under another contract?
Yes. 75N92023F00003 is a delivery order under 75N92022D00013, an indefinite delivery contract.
Was contract 75N92023F00003 competed?
The extent of competition for 75N92023F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award